|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization expense | |||||
| Amortization of debt discount and issuance costs | |||||
| Accretion of discount on investments in debt securities | |||||
| Equity-based compensation expense | |||||
| Goodwill impairment | |||||
| Pangiam Acquisition | |||||
| Total goodwill impairment | |||||
| Impairment of right-of-use assets | |||||
| Impairment of long-lived assets | |||||
| Non-cash lease expense | |||||
| Provision for doubtful accounts | |||||
| Deferred income tax benefit | |||||
| Loss on extinguishment of debt | |||||
| Increase in fair value of derivatives | |||||
| Loss on sale of property and equipment | |||||
| Changes in assets and liabilities: | |||||
| Decrease (increase) in accounts receivable | |||||
| Decrease (increase) in contract assets | |||||
| Decrease (increase) in prepaid expenses and other assets | |||||
| Decrease in accounts payable | |||||
| (Decrease) increase in accrued expenses | |||||
| Increase (decrease) in contract liabilities | |||||
| Increase (decrease) in other liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of investments in debt securities | |||||
| Sales of AFS investments | |||||
| Acquisition of business, net of cash acquired | |||||
| Purchases of property and equipment | |||||
| Capitalized software development costs | |||||
| Net cash (used in) provided by investing activities | |||||
| Cash flows from financing activities: | |||||
| Repurchase of shares as a result of forward share purchase agreements | |||||
| Repayment of term loan | |||||
| Proceeds from warrant exercises | |||||
| Proceeds from issuance of Private Placement and Registered Direct Offering shares | |||||
| Payment of Private Placement and Registered Direct Offering transaction costs | |||||
| Proceeds from short-term borrowings | |||||
| Repayment of short-term borrowings | |||||
| Proceeds from issuance of convertible notes | |||||
| Proceeds from at-the-market offering | |||||
| Payment of transaction costs for at-the-market offering | |||||
| Payment of debt issuance costs to third parties | |||||
| Issuance of common stock upon ESPP purchase | |||||
| Proceeds from exercise of options | |||||
| Payments of tax withholding from the issuance of common stock | |||||
| Net cash provided by financing activities | |||||
| Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash | |||||
| Net increase in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents, and restricted cash at the beginning of the period | |||||
| Cash, cash equivalents, and restricted cash at the end of the period | |||||
| Cash paid (received) during the period for: | |||||
| Interest | |||||
| U.S. federal | |||||
| U.S. state and local | |||||
| Foreign | |||||
| As previously disclosed, prior to the adoption of ASU 2023-09 | |||||
| Supplemental schedule of non-cash investing and financing activities: | |||||
| Issuance of common stock upon conversion of 2029 Notes | |||||
| Issuance of common stock for paid-in-kind interest on 2029 Convertible Notes | |||||
| Transfers of debt securities from held-to-maturity to available for sale | |||||
| Issuance of common stock for exercise of RDO and PIPE warrants, net of cash received | |||||
| Deferred purchase consideration for the acquisition of Ask Sage included in other current liabilities | |||||
| Issuance of common stock as consideration for Pangiam acquisition | |||||
| Gig Business Combination transaction costs paid included in accrued liabilities | |||||
| Gig Business Combination costs settled through issuance of common stock | |||||
| Debt issuance costs settled through issuance of common stock | |||||
| Initial fair value of written put option at closing | |||||
| Initial fair value of private warrants at closing | |||||
| Reconciliation of cash, cash equivalents, and restricted cash: | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
Loading...